IBM's Red Hat Offensive Aims at Cloud Migration as Consulting Stagnation Weighs on Shares

IBM shares touched a fresh 52-week low of €187.10 earlier this week, capping a nearly 25% slide since the start of the year. The selloff has been brutal by any measure, yet the company's first-quarter numbers tell a starkly different story. Revenue climbed almost 10% to $15.9 billion, adjusted earnings per share of $1.91 came in ahead of analyst estimates, and the mainframe business posted a stunning 51% jump in sales. So why is the market reaching for the sell button?

The disconnect boils down to two factors: a cautious full-year outlook and a consulting arm that refuses to gain momentum. Management merely reiterated its 2026 guidance for currency-adjusted revenue growth above 5%, dashing hopes that the beat would trigger an upgrade. Meanwhile, the consulting segment — a key profit-driver in the past — eked out just 1% growth on a constant-currency basis. Tight corporate budgets and government austerity measures are squeezing client spending, and the rise of AI tools like Anthropic's Claude Code threatens to further erode demand for traditional IT advisory work.

IBM is countering with a product blitz aimed at the cloud and AI infrastructure market. In May, the company will launch Red Hat AI Inference, a managed service that lets enterprises deploy models like Granite 4.0 and Llama 3.3 without the hardware headache. That will be followed in June by Red Hat OpenShift Virtualization Service, designed to help companies migrate from legacy virtual machines to modern container environments. The overarching strategy, dubbed "metal-to-agent," promises a unified platform spanning bare metal all the way to autonomous AI agents — with a heavy emphasis on data sovereignty and security for regulated industries.

Should investors sell immediately? Or is it worth buying IBM?

That regulatory focus is becoming a competitive moat. IBM's Sovereign Core offering and the recently acquired Confluent assets are central to winning contracts in finance, healthcare, and government. The Confluent deal, however, carries a near-term price tag: it is expected to shave roughly $600 million from earnings per share this year. Management is betting the long-term strategic fit will justify the drag, but investors have so far been unimpressed.

Wall Street remains broadly constructive despite the stock's slide. DZ Bank rates IBM a buy with a $295 price target, HSBC upgraded the shares to hold at $231, and the consensus across 15 analysts stands at roughly $291 — implying substantial upside from current levels. Morgan Stanley has praised the company's pivot from a pure AI hardware supplier to a full-stack enterprise AI provider anchored by the Watsonx platform.

Short-term, shareholders can take some solace in a quarterly dividend increase to $1.69 per share, extending a decades-long payout streak. The real test will come with second-quarter earnings, when management must demonstrate that the consulting engine is finally shifting out of first gear. Until then, the gap between operational strength and market sentiment looks likely to persist.

Ad

IBM Stock: New Analysis - 13 May

Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated IBM analysis...

en | US4592001014 | IBMS | boerse | 69324326 |